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Commentary
As to metabolic syndrome (Met-S), the frequency of hypertension 
and diabetes increases with the progress of arteriosclerosis. Its 
pathophysiological mechanism also involves the control of the nervous 
system. In other words, regarding the adjustment of blood pressure in 
humans, the blood pressure will fluctuate by adjusting mechanism of 
the nervous system, corresponding to the body position, movement, 
exercise and psycho-psychiatric changes in various situations. There is 
no problem in normal persons concerning these regulatory mechanisms. 
However, in the patients associated with hypertension or previous 
stroke, the mechanism for instantaneously regulating blood pressure 
has been impaired. Therefore, blood pressure may rise or fall suddenly 
in such patients. 
In this article, I would like to describe recent various findings 
related to Met-S, hypertension and diabetes and introduce our study 
results concerning discontinuation of antihypertensive drug. Met-S 
was originated and studied from syndrome X in 1980s [1,2]. Since then 
several kinds of diagnostic criteria have been found in each association 
and country [3]. In recent years, prevalence of Met-S has been gradually 
elevated for decades, including medical, social and economic problems 
[4-6]. This tendency has been spread in every country [7]. 
Met-S has been also defined as a cluster of interconnected metabolic 
abnormalities accompanied by glucose metabolism. They also include 
dyslipidemia, elevated blood pressure and central obesity [8].
According to lots of reports so far, Met-S increases the risk of death 
from all causes including type 2 diabetes and cardiovascular disease 
[9]. Furthermore, Met-S is also associated with other co-morbidities 
including thrombosis and pro-inflammatory conditions, non-alcoholic 
steatohepatitis and reproductive disorders and certain types of cancer 
[10]. 
Hypertension included in Met-S has been called ‘silent killer’. 
Without any symptoms, it always exacerbates arteriosclerosis for years. 
The frequency is high in each country worldwide and its treatment, care 
and prevention for hypertension would be important from adulthood to 
middle-aged and elderly. Therefore, in recent years, various guidelines 
have been presented in each country. 
There have been several guidelines for hypertension and heart 
disease, in Japan [11], in North American region [12,13] and in European 
countries [14,15]. In addition, some related guidelines for patients with 
lipid and obesity are found [16,17] and guidelines for young generation 
and the elderly have been also presented in recent years [18,19]. In 
the future, treatment and management for hypertension would be 
continued for comprehensively utilizing these guidelines for patients 
with metabolic syndrome suffering from some diseases. 
To investigate the treatment of many patients, two dimensional 
viewpoints of warp and weft are important, which is longitudinal thread 
and transvers thread, respectively. The former is medical treatments on 
hypertension for several decades. On contrast, the latter is to examine 
and evaluate various data in epidemiological way. 
There are some examples as follows: how many people are already 
treating with hypertension, how many people have hypertension 
tendency in preclinical stage, how much extent does certain anti-
hypertensive drug lower the blood pressure in the relevant population, 
what kind of treatment or care should be done for hypertension in a 
certain country, what kind of beneficial outcome will be expected by this 
policy and so on [20]. Among them, in addition to drug administration, 
it will be necessary to investigate and examine the contents and effects 
of “non-drug therapy” for hypertension [21]. 
Non-medicinal therapy usually means our lifestyle, including meal, 
exercise, rest, alcohol and smoking. There has been 2017 High Blood 
Pressure Clinical Practice Guideline, which is a Report of the American 
College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines [13]. It showed six aspects for recommendations for 
non-pharmacological interventions at the level of 1-A. 
These are summarized to weight loss [22], a heart-healthy diet such 
as the DASH (Dietary Approaches to Stop Hypertension) diet [21], 
sodium reduction [23], potassium supplementation [24], increased 
physical activity [25] and reduction in alcohol consumption [26]. 
The author and colleagues investigated lot of hypertensive cases who 
could discontinue the administration of anti-hypertensive drugs [27]. 
We have thousands of cases of hypertension in a year, in which 4.6%-6.1% 
cases could stop antihypertensive drugs in a few years. For example, 50 
cases with each 25 in male and female were studied in detail. There were 
family histories of hypertension 33 cases (66%) in women, smoking 76% 
in men, alcohol consumption 60% in men, 42% for dyslipidemia 42% 
and type 2 diabetes mellitus (T2DM) 12%. The frequency of 12% may be 
lower than expected, in comparison with others.
For these results, some possible reasons were speculated. Diabetic 
status can cause microangiopathy and macroangiopathy associated 
with neuropathy including peripheral and autonomic regulation. Then, 
hypertensive patients with diabetes may be rather difficult to discontinue 
antihypertensive drugs because of impaired mechanism of neural and 
vascular regulation of blood vessels. Probably, the cases with successful 
discontinuation of drug may have several necessary factors with light 
hypertension, regular life, limited status of obesity, diabetes and other 
influential impairments.
Moreover, discontinuation of antihypertensive treatment is affect by 
a large number of factors in a real life setting [28]. They include type 
of antihypertensive treatment, co-treatments, clinical conditions, social 
and environmental factors where the patient lives.
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As for the diabetes guidelines, changes have been observed recently. 
American Diabetes Association (ADA) followed the joint algorithm 
of European Diabetes Society (EASD) 2012 [29] until 2017 [30]. For 
example, metformin is used as an initiator, and various drugs are listed 
as horizontal lines.
On contrast, recommendations were changed in the 2018 edition 
[31]. Metformin is used as a single agent. When HbA1c is 9% or more, 
2 agents with metformin+other drug are used. When HbA1c is 10% or 
more, 3 agents with metformin+other drugs or insulin therapy would 
be considered.
Furthermore, American College of Physicians (ACP) showed 
official comments concerning diabetes in 2017 [32]. It has surprising 
recommendations with a paradigm change. There was Statement 2, in 
which clinicians should set the management goal for HbA1c in most 
T2DM patients to be 7% or more and less than 8%.
Consequently, we can find large paradigm changes in also 
diabetes field. We would continue medical practice with attention to 
the management of hypertension and diabetes using adequate and 
satisfactory guideline as well as respecting QOL/ADL and psychological 
desire of the patients from now.
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